A meta-analysis study on the use of glibenclamide in GDM women found the drug to be as effective as insulin therapy however the risk of developing neonatal hypoglycemia, high fetal birth weight, and macrosomia were increased in women treated with glibenclamide [52]. The gene discussed is INS; the disease is gestational diabetes.